Dianthus Therapeutics DNTH Income Statement
| TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | TTM Q3 '24 | ||
|---|---|---|---|---|---|---|
| $3.08M-42.6% | $4.85M+17.9% | $6.52M— | $6.24M— | $5.37M— | ||
| $116.95M+78.6% | $110.01M+130% | $101.83M+154% | $87.9M+168% | $65.47M+93.2% | ||
| $31.23M+37.0% | $29.56M+18.3% | $26.69M+24.2% | $24.99M+37.6% | $22.8M+46.5% | ||
| $143.39M+62.4% | $134.77M+84.9% | $123.72M+101% | $108.1M+112% | $88.27M+78.5% | ||
| -$140.31M-69.2% | -$129.92M-88.9% | -$117.2M-101% | -$101.86M-111% | -$82.9M-80.6% | ||
| -4,558.4%-3,013pp | -2,676.6%-1,007pp | -1,796.4%— | -1,633.7%— | -1,545%— | ||
| $13.96M-11.7% | $15.17M+25.5% | $16.47M+103% | $16.9M+266% | $15.81M+464% | ||
| -$126.35M-88.3% | -$114.75M-102% | -$100.73M-101% | -$84.97M-95.1% | -$67.09M-55.6% | ||
| -4,104.8%-2,854pp | -2,364.1%-988pp | -1,544%— | -1,362.8%— | -1,250.3%— | ||
| -$3.49— | -$3.26— | -$2.89— | -$2.61— | —— | ||
| -$140.2M-69.3% | -$129.81M-89.0% | -$117.1M-101% | -$101.77M-113% | -$82.81M-84.1% | ||
| -4,554.8%-3,012pp | -2,674.3%-1,007pp | -1,794.8%— | -1,632.2%— | -1,543.3%— | ||
| -$140.31M-69.2% | -$129.92M-88.9% | -$117.2M-101% | -$101.86M-111% | -$82.9M-80.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's income statement data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.